TwitterLinkedin

Contact Us

  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Our Milestones
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Development Strategy and Gap Analysis
            • Integrated Product Development
            • Market Access Strategy
            • Non-clinical Development Concept
              and Study Design
            • Scientific Advice
            • Scientific Due Diligence
            • Statistical Services
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Orphan Drug Designation
            • Pediatric Investigation Plan (PIP)
            • Scientific Advice
            • Statistical Services
          • Regulatory Affairs

            • Clinical Trial Applications (CTA)
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • IMP Management
            • Interim / Contract QA
            • Quality Systems
            • Tech Transfer / Scale-up
            • Vendor Management and Oversight
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistical Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Environmental Risk Assessment
            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • Audit and CAPA Management
            • EU QPPV / National QPPV
            • ICSR Management
            • Literature Screening
            • Pharmacovigilance Systems
            • Safety Writing (PSUR, RMP)
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • Good Distribution Practice (GDP) Compliance
            • GxP Services
            • Interim / Contract QA
            • Quality Systems
            • Vendor Audit
            • Vendor Management and Oversight
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
            • Medical Information
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • Consulting
            • Consumer Healthcare
            • Generics
            • Herbal Medicines
            • Medicinal Products
            • MedTech Services
            • Pharmaceutical
            • Veterinary Drugs
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • Brexit
            • COVID-19 Support
            • Drug Re-purposing / Value-added Medicines
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Statistical Services
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • News
    • Webinars
    • Events
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Working at PharmaLex
    • Your Application Process
    • Career Opportunities
  • Training
Home > Our Services > COVID-19 Support

COVID-19 Support

Together Beyond COVID-19

To get answers to your COVID-19 questions, why not #AskTheExperts at PharmaLex?

#AskTheExpert

We find ourselves in one of the most challenging situations in history. In a very short time, the world has been consumed by a virus that has proved to be both ruthless and deadly. Countries all over the world are battling an invisible enemy and yet remain resolute in the face of such adversity.

COVID-19 is evolving daily and represents an enormous challenge to public health, society and organizations seeking to maintain business operations. It is therefore imperative that we are able to react quickly and effectively. As a company we are closely monitoring the situation and have set-up a taskforce to recommend and communicate how we can take consistent approaches together to support our clients, protect our employees and our business during this pandemic. We see this as an opportunity to learn, grow, innovate and increase in flexibility. This is beyond corporate social responsibility, it’s way more – both as healthcare professionals and individuals. Our combined expertise can really make a difference and we are committed to going above and beyond to fight this as an industry.

However, despite the current crisis, product development continues and regulatory compliance, quality management and on-going pharmacovigilance must be maintained. It is important to also look beyond COVID-19 and have a strategy in place to manage this. Planning at a local level will help boost resources and ensure delivery plans are aligned when the time comes. Now is the opportunity to put in place fail-safe measures that will ensure business can continue now and will continue and grow when the crisis is over.

It is in times such as these that we can ensure that we work together. We are proud that we continue to support our clients and provide the necessary backbone which allows our industry to deliver.

Our approach is straightforward – we have experts across the globe who understand the current challenges and deliver solutions remotely. Our experts are available to answer your questions #AskTheExpert. Our IT infrastructure includes cloud-based technologies, and now more than ever, we see its value. Whilst on-site services are inevitably affected, our flexible team of committed experts is tailoring our solutions to your changing circumstances and has adopted a virtual approach wherever possible to deliver now and BEYONDCOVID19 – business continuity.

We remain dedicated to ensuring our clients can continue their vital work at a time when it is needed more than ever. Together Beyond COVID-19.

COVID-19 NEWSLETTER SIGN UP

“How to mitigate manufacturing site closures?”

“What to do when clinical trials are closed / postponed?”

“How to manage interruptions or slow-down of business processes?”

“What are the alternatives to face-to-face audits?”

“Are frozen budgets affecting development strategy?”

“How to maintain legacy portfolios without necessary resource?”

“Getting a slower response from regulators?”

Related PharmaLex News

medical devices digital health era
Medical Devices in the Digital Health Era
10th December 2020
Covid19 -Impact on Compliance and Quality Culture
22nd September 2020
Society of Quality Assurance (SQA) Virtual Meeting and Quality College
SQA, Virtual Meeting and Quality College 2020
2nd September 2020

Related Resources

Thought Leadership

  • The Outlook for a Year of Change
  • Together Beyond COVID-19

White Papers

  • Together Beyond COVID-19: Key trends that have been accelerated by the pandemic

Infographics

  • Virtual Auditing for GxP Compliance

COVID-19 Authority Updates

News Feed

Highlighted services PharmaLex can provide virtually during COVID-19

The outbreak of COVID-19 has resulted in the requirement for the majority of personnel in technical companies to work remotely. The situation is evolving globally, and pragmatic actions are required to deal with the challenges faced by companies who need to conduct business and maintain compliance while also ensuring the safety and wellbeing of all personnel.  As a result, companies are making contingency plans in preparation for the spread of COVID- 19 to ensure business continuity during this time.

Most recently for example, the European Medicines Agency (EMA) and US Federal Drug Administration (FDA) have updated guidance on the management of clinical trials during the Coronavirus pandemic to allow services to be conducted remotely as an alternative to physical visits in order to mitigate the risk posed by the COVID-19 pandemic on the conduct of clinical trials. Further information is available at the following link:

https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/guidanceclinicaltrials_covid19_en.pdf

https://www.fda.gov/media/136238/download

As on-site visits to client facilities are generally not permitted during this time, a contingency plan in line with the updated EMA guidance has also been adopted by PharmaLex to support our clients during this difficult time.

PharmaLex are well placed to offer consultancy services in the current climate and have an extensive global network of personnel located in offices in over 21 countries who understand the current challenges faced by clients and in response are ready to deliver solutions remotely as follows:

Our experts will be available to answer your questions on the PharmaLex webpage using #AskTheExpert.

Our secure IT infrastructure includes cloud-based technologies, and now more than ever we see its value. Our flexible team of experts have adopted a virtual approach wherever possible to deliver now and beyond COVID-19 to ensure business continuity.

Below are a range of services PharmaLex can provide remotely during COVID-19, including and not limited to:

Strategic Consultancy

  • Provide advice on short-, mid- and long-term strategies resulting from the current situation
  • Help get an overview on the working-status of Health authorities worldwide and help mitigate in situations where agencies are unable to work at capacity or even not reachable
  • Can act quickly, if you are facing shortages in Regulatory affairs personnel
  • Help define second-supplier-strategies for APIs, other excipients and drug product production (resulting for example in site transfers of APIs from China/India to Europe)

Clinical Trial Applications

  • Provide strategies on protocol deviations and amendments in relation to COVID-19
  • Has a global team to support in submitting formal amendments or supplements for trials in the respective countries or areas
  • Can foster the process to implement strategies for applying accelerated approvals by authorities and ethic committees

Virtual workshops to identify development, compliance and regulatory requirements

  • Conduct workshops relating to a wide range of development quality compliance and regulatory topics to determine the scope of work and to develop a work plan or road map outlining the specific deliverables that will allow us to meet your requirements
  • Virtual workshops can now be conducted remotely through virtual conferencing and virtual meeting software capability which allows team members to brainstorm ideas, exchange feedback and remain focused on the task in-hand

Development of Quality Management System documentation

  • Can develop Quality Management System documentation for clients remotely as follows:
    • Conduct a workshop or teleconference meeting with the client remotely to understand their business model and regulatory obligations
    • Develop the required documentation such as SOPs, Policies, Quality Agreements, Quality Manual, Site Master File, Protocols and Reports and work with the client to ensure a seamless transfer of documents from PharmaLex to the client
    • Regular team meetings with the client using the latest software tools for communication to provide an up to-date status of the work

Staff augmentation (Qualified Person, Responsible Person, Quality Assurance Subject Matter Experts)

  • Can provide contract staff for the above listed roles that can work remotely for the client

GxP Audits

In the life science and pharmaceutical industry, audits are necessary to comply with regulations and to ensure the quality of products. The understanding is that if manufacturing is continuing, so should a meaningful program of audits. Fortunately, PharmaLex offers ‘virtual audits’, thereby conducting an audit without being physically present at the auditees facility as follows:

Conduct a Risk Assessment to determine the urgency and requirement to conduct the audit.

  • If following this assessment, it is deemed necessary to conduct the audit, the following Virtual Audit activities are recommended:
  • Perform a desktop audit by providing a detailed audit questionnaire to the auditee containing a list of relevant questions and requesting pertinent site documents
  • A remote audit can be conducted by virtual conference with the client and utilising screen sharing software to share any media securely on your device without the need to transmit proprietary files e.g. presentations, images and even videos
  • If possible, conduct a tour of the facility virtually using site layout drawings, approved photos or videos that are presented by the SME on the conference call
  • Provide the audit report and support the client and auditee with closure of any actions outline in the audit report

Medical Device Regulation (MDR)

The outbreak of COVID-19 has also forced a delay of the MDR application from the 26th May 2020 by one year to May 2021.

  • Further information on the European Commission’s announcement can be found here.

PharmaLex leverages over 20 years of Medical Device expertise with experts in this field that can provide the required support remotely to ensure the client meets this international regulation. The below page provides further information on the activities PharmaLex can provide remotely to meet this deadline:

  • PharmaLex Medical Device Services

Regulatory Expectations for Medicinal Products for Human use during the Covid-19

Marketing Authorization Marketing Authorization and Procedures Medicinal Product to be used for
COVID-19 patients
Approved? YES NO Approval acc. Article 5(2) (Dir 2001/83/EC) Approval acc. Article 27 (Dir. 2001/83/EC) Approval acc. Article 126a (Dir. 2001/83/EC) "Compassionate use" "Day 0 MRP / RUP to expand MA to new Member States" "Member State may authorize the placing on the market" "Temporary authorization of the destribution of an unauthorized medicinal product"
Renewals Renewals at least nine months before the marketing authorization ceases to be valid Inititial Marketing Authorization is valid for five years Renewal application becomes applicable Request to postpone renewal submission based on justification Contact the EMA (for centrally authorized products) or the reference Member State (for products authorized under the MRP / DCP) before the foreseen deadline with a justified request to postpone the submission to a later point in time. Sunset-Clause Sunset-clause Three years period is expiring Initial Marketing Authorization will cease to be valid if not placed on the market within three years of its granting or for a period of three consecutive years. Sunset clause
becomes effective
Request for
exemption
For centrally authorized products: European Commission. For nationally authorized products: competent authorities of the Member State(s) concerned.
Quality variations ECMP (Exceptional Change Management Process) Crucial medicines
for use in COVID-19 patients
MAH must notify the relevant EMA/NCA about use of ECMP Within two working days, the MAH will be informed whether the relevant competent authority has agreed to the application of the ECMP Implementation
of required
change
Not later than 6 months Within 48 hours Submission of Variation application Submission of
Notification to EMA / NCA
Within 48 hours Approval by
EMA / NCA
Marketing Authorization Renewals Sunset-clause Quality Variations incl. Exceptional Change Management Process (ECMP)
If you would like advice or support in relation to the services PharmaLex can provide remotely during COVID-19 please get in touch to find out more on the range of services that we offer and how we can help you by connecting with us by email at contact@pharmalex.com.

Our client commitment

In these unprecedented times, PharmaLex continues to support all clients by meeting virtually and providing experienced, remote-based consultants.

PharmaLex Team Thomas
Thomas Dobmeyer, CEO PharmaLex
CEO PharmaLex
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
Tweets by @PharmaLexGLOBAL
COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2021 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit Logo

#AskTheExpert #TogetherBEYONDCOVID19





    Select your state:

    .
    You can unsubscribe at any time at data.protection@pharmalex.com

    If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

    #TogetherBEYONDCOVID19

    We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for

      Please DO NOT send us event/conference information.
      We will not respond and these will be deleted immediately.





      Select your state:

      .
      You can unsubscribe at any time at
      data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      Privacy Policy

      This can be specific information about signing up to the newsletter.

      Pellentesque lobortis, tellus at ultrices ullamcorper, lectus tellus consectetur lectus, id consequat leo quam quis eros. Mauris pellentesque tortor a augue pellentesque ultricies. Phasellus sit amet suscipit orci, vel dapibus ligula. Maecenas at pellentesque lectus, sit amet tristique felis. Integer fringilla risus ac neque mollis, at imperdiet lacus sodales. In vehicula orci sed vulputate interdum. Nunc sagittis non nunc eget sollicitudin.

      Maecenas a mattis erat. Phasellus cursus erat non nisl pulvinar ultricies. Aenean id fringilla libero. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Morbi in ultrices elit. Suspendisse egestas hendrerit est. Integer pellentesque nisl ut justo tempus, nec suscipit dolor luctus. Cras vestibulum elementum tincidunt.

      In compliance with the Spanish Law 15/1999, of Protection of Personal Data and in accordance with regulations approved by the Spanish RD 994/1999 inform you that your data will be part of a file located in Friedrichsdorf (Germany), whose ownership belongs to Pharmalex Spain S.L.U. The purpose of these data is the insertion in a potential job selection process. Inform the user that at any time may exercise their right of access, rectification, and deletion of data through email curriculum@pharmalex.com or to this postal address Pharmalex Spain. Coso 103, 50001 Zaragoza, Spain.